RT Journal Article SR Electronic T1 Three new drugs for type 2 diabetes JF Drug and Therapeutics Bulletin JO Drug Ther Bull FD BMJ Publishing Group Ltd SP 49 OP 52 DO 10.1136/dtb.2008.06.0014 VO 46 IS 7 YR 2008 UL http://dtb.bmj.com/content/46/7/49.abstract AB Relevant BNF section: 6.1.2.3For many patients with type 2 diabetes mellitus, metformin plus appropriate treatment for cardiovascular risk factors form the cornerstone of drug therapy.1 However, the progressive impairment of both the secretion and action of insulin in the condition mean that high blood glucose concentrations usually worsen over time, so necessitating escalation of hypoglycaemic therapy.1 Three drugs in two new classes that act on the hormonal regulation of insulin secretion have been launched recently for use as add-in therapies in patients with type 2 diabetes: ▼exenatide (Byetta – Eli Lilly), ▼sitagliptin (Januvia – MSD), and ▼vildagliptin (Galvus – Novartis). Here we consider whether they have a role in the management of such individuals.